Russian Heart Failure Journal 2014year Repeated infusions of levosimendan in a patient with resistant CHF and left renal aplasia (case report)

To access this material please log in or register

Register Authorize

Repeated infusions of levosimendan in a patient with resistant CHF and left renal aplasia (case report)

Fedorova M. V., Petrova E. B., Fomin I. V.

Keywords: treatment, kidneys, CHF

DOI: 10.18087/rhfj.2014.2.1921

  1. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю., Беленков Ю. Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4–7.
  2. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распростра­ненность хронической сердечной недостаточности в Европей­ской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (3):112–115.
  3. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  4. Papp Z, Csapo K, Pollesello P et al. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev. 2005;23 (1):71–98.
  5. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999;288 (1):316–325.
  6. Bayram M1, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005;96 (6A): 47G-58G.
  7. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs ac­ting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4 (4):515–529.
  8. Metra M, Eichhorn E, Abraham WT et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009;30 (24):3015–3026.
  9. Abraham WT, Adams KF, Fonarow GC et al. In-hospital morta­lity in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46 (1):57–64.
  10. Mebazaa A1, Parissis J, Porcher R et al. Short-term survival by treatment among patients hospitalized with acute heart failure: The global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37 (2):290–301.
  11. Landoni G1, Mizzi A, Biondi-Zoccai G et al. Levosimendan redu­ces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol. 2010;76 (4):276–286.
  12. Edes I, Kiss E, Kitada Y et al. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phospho­rylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995;77 (1):107–113.
  13. Pollesello P, Ovaska M, Kaivola J et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994;269 (46):28584–28590.
  14. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360 (9328):196–202.
  15. Moiseyev VS, Poder P, Andrejevs N et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A rando­mized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23 (18):1422–1432.
  16. Michaels AD, McKeown B, Kostal M et al. Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake. Circulation. 2005;111 (12):1504–1509.
  17. Gheorghiade M1, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol. 2005;96 (6A): 68G-73G.
  18. Huelsmann M, Moerti D, Bojic A et al. The Ca2+-sensitizer levosimendan versus prostaglandin E1 as a bridge to increased beta-blockade in patients with refractory decompensated chronic heart failure. Eur Heart J. 2004;25 (Suppl): abstract 3639.
  19. Bojic A, Huelsmann M, Berger R et al. Short-term effects of levosimendan versus prostaglandin E1 on haemodynamics and BNP plasma levels in patients with chronic heart failure. Eur Heart J. 2004;25 (Suppl): abstract 3654.
  20. Spargias KS1, Anifantakis A, Papadakis M et al. Preliminary clinical experience with the repetitive administration oflevosimendan in patients with end-stage heart failure. Ital Heart J. 2003;4 (Suppl 2):45S-49S.
  21. Mavrogeni S1, Giamouzis G, Papadopoulou E et al. A 6‑month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail. 2007;13 (7):556–559.
  22. Parle NM1, Thomas MD, Dembo L et al. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure – a single-centre experience. Heart Lung Circ. 2008;17 (3):206–210.
  23. Parissis JT1, Adamopoulos S, Farmakis D et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. 2006;92 (12):1768–1772.
Fedorova M. V., Petrova E. B., Fomin I. V. Repeated infusions of levosimendan in a patient with resistant CHF and left renal aplasia (case report). Russian Heart Failure Journal. 2014;83 (2):132–136

To access this material please log in or register

Register Authorize
Ru En